Effectiveness of simple lidocaína 2% applied in the subcutaneous tissue as prevention of infection in operative site of cesaera
Hospital Simon Bolivar of Barranquilla-January-April 2013
Keywords:
Lidocaine, Prophylaxis, Infection control, Cesarean section.Abstract
Objective: Determine the effectiveness of simple 2 % lidocaina applied in the subcutaneous tissue as prevention of infection in operative site of cesarea in Hospital Simon Bolivar of Barranquilla during the period January-April of 2013. Materials and Methods: Controlled clinical trial, in over 18 years old (≥ 37 weeks pregnant) patients undergo- ing scheduled cesarea through obstetrics and gynecology service of Hospital Simon Bolivar of Barranquilla, who agreed to be linked to the study, the sample consisted of 50 patients for each group. Lidocaine group: Simple lido- caine 2 % was applied (10 ml) in the subcutaneous tissue of the surgical wound. Control group: Prophylaxis wasn’t applied, information was tabulated using Epi-Info 3.5.1. Results: In the group that used lidocaine as prophylaxis, the incidence of surgical site infection was 2 % compared with 16 % in the control group (OR = 0.10, CI = 0.01-0.89, p-value = 0.01); with statistically significant differences in favor of the effectiveness of the application of simple lidocaine 2 % (10 ml) in the subcutaneous tissue of the surgical wound. Conclusion: Applying simple 2 % lidocaine (10 ml) in the subcutaneous tissue of the surgical wound at the time of cesarean raffia, is an effective and safe prophylaxis of surgical site infection.
Downloads
References
2.Notzon FC. International differences in the use of obstetric interventions. JAMA. 2000; 103-09.
3.Villar J, Valladares E, Wojdyla D, Zavaleta N, Carroli G, Velazco A, Shah A, et al. For the who 2005 global survey on maternal and perinatal health research group. Caesarean delivery rates and pregnancy outcomes: the 2005 WHO global survey on maternal and perinatal health in Latin America. Lancet. 2006; 367: 1819-27.
4.Nielsen TF, Hokegard RH. Post operative ce- sarean section morbidity: A prospective stu- dy. Am J Obstet Gynecol. 2003; 184:68-9.
5.Centro Regional de Investigaciones. México, D. F. Multidisciplinarias, Sociedad Mexicana de Demograña 1a edición, Ciudad de México, 2008; 67-74.
6.Goodman L, Gilman A. Bases farmacológicas de la terapéutica médica. 9ª edición. México, D.F.: Editorial Interamericana McGraw-Hill. 2001.
7.Giddon DB, Lindhe J. In vivo quantitation of laar anesthetic Suppression of Leurocyte ad- herence. Am J Pathol. 1972; 68:327-338.
8.Schmidt RM, Rosenkranz HS. Antimicrobial activity of local anesthetics, lidocaine and procaine. J Infect Dis. 1970; 4:115-19.
9.Rabinovitch M, Destefano MJ. Cell shape changes induced by cationic anesthetics. J Exp Med. 1976; 143:290-304.
10.Cullen BF, Haschkel RH. Local anesthetic in- hibition of phagocytosis and metabolism of human leukocytes. Anesthesiology. 1974; 40:142-146.
11.Schiffer CA, Sanel FT. Reversal of granulo- cyte adherence to nylon fibers using local anesthesic agents: possible application to fil- tration leukapheresis. Blood. 1977; 50:213- 25.
12.MacGregor RR, Thorner RE, Wright DM. Li- docaine inhibits granulocyte adherence and prevents granulocyte delivery to inflam- matory sites. Blood. 1980; 56:203-9.
13.Rosenberg PH, Renkonen OV. Antimicrobial activity of bupivacaine and morphine. Anes- tesiology. 1985; 62:178-9.
14.Eriksson AS, Sinclair R, Cassuto J. Influence of lidocaine on leucocyte function in the surgi- cal wound. Anesthesiology. 1992; 77:74-8.
15.Aritzi GP. Aplicación de lidocaína en el tejido celular subcutáneo para la prevención de in- fección de la herida quirúrgica en un modelo experimental. Cir Gen. 1999; 19(2):120-3.
16.Hospital General de Barranquilla. Eficacia de la lidocaina simple al 2 % aplicada en el tejido celular subcutaneo de heridas limpias-conta- minadas y contaminadas como profilaxis de infección del sitio operatorio. No publicado, 2012.
Downloads
Published
Issue
Section
License
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.